Abstract
OBJECTIVE:
To determine the exercise capacity of children and adolescents with Friedreich's Ataxia (FA) and to evaluate the effects of 6 months of idebenone treatment on exercise capacity.
DESIGN:
Exploratory endpoint in a randomized double-blind, placebo-controlled, phase II clinical trial designed to investigate the effects of idebenone on a biomarker of oxidative stress.
SETTING:
Exercise physiology laboratory in a single clinical research center.
Exercise Capacity and Idebenone Intervention in Children and Adolescents With Friedreich Ataxia